This clinical trial studies the treatment of blood cancers including Multiple Myeloma, Non-Hodgkin B-cell lymphoma, and B-cell Acute Lymphoblastic Leukemia that have either returned after previous treatment or did not respond to standard treatments. The study uses a new treatment called LUMC-BOB1-B7-TCR.1, which is made from the patient’s own immune cells (specifically T cells) that have been modified in a laboratory to better fight cancer cells.
The purpose of this study is to determine if this new cell therapy treatment is safe to use and if it works effectively against these blood cancers. The treatment is given as an intravenous infusion, which means it is delivered directly into the bloodstream through a vein. This is a combined Phase 1 and Phase 2 study, where Phase 1 focuses on finding the right dose of the treatment, and Phase 2 examines how well the treatment works.
The treatment involves taking some of the patient’s own immune cells, modifying them in a laboratory to recognize and attack cancer cells, and then returning them to the patient through an infusion. After receiving the treatment, patients will be monitored for side effects and to see how their cancer responds to the therapy. The study specifically looks at patients whose cancer cells have a particular genetic marker called HLA-B*07:02.
The Netherlands 
